Q&A: Assessing Current Evidence & Approaches for Treating HCC
ASCO guidelines for hepatocellular carcinoma (HCC) are based on nine randomized phase 3 clinical...
Read MoreSep 7, 2023
ASCO guidelines for hepatocellular carcinoma (HCC) are based on nine randomized phase 3 clinical...
Read MoreSep 6, 2023
Open radiofrequency ablation, splenectomy, and pericardial devascularization for small hepatocellular carcinomas with portal hypertension and hypersplenism represent an alternative therapeutic option for carefully selected...
Read MoreSep 5, 2023
Early tumor shrinkage (ETS) and depth of response (DpR) are effective tools for prognostication in patients with advanced, chemotherapynaïve biliary tract cancer, according to findings published in The Oncologist. Investigators...
Read MoreSep 3, 2023
Hepatocellular carcinoma (HCC) comprises 75% of all liver cancer diagnoses in the United...
Read More